X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (20068) 20068
Book Chapter (40) 40
Magazine Article (35) 35
Dissertation (16) 16
Newspaper Article (13) 13
Publication (12) 12
Book / eBook (7) 7
Book Review (7) 7
Newsletter (7) 7
Conference Proceeding (6) 6
Reference (6) 6
Web Resource (6) 6
Paper (2) 2
Government Document (1) 1
Journal / eJournal (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (13488) 13488
imatinib mesylate (11908) 11908
index medicus (8172) 8172
benzamides (6848) 6848
male (6129) 6129
female (5442) 5442
oncology (5312) 5312
pyrimidines - therapeutic use (4964) 4964
piperazines - therapeutic use (4749) 4749
antineoplastic agents - therapeutic use (4371) 4371
middle aged (4299) 4299
animals (3914) 3914
adult (3789) 3789
leukemia, myelogenous, chronic, bcr-abl positive - drug therapy (3633) 3633
imatinib (3327) 3327
aged (3266) 3266
hematology (3118) 3118
pyrimidines - pharmacology (2514) 2514
chronic myelogenous leukemia (2472) 2472
treatment outcome (2397) 2397
piperazines - pharmacology (2367) 2367
chronic myeloid-leukemia (2263) 2263
cancer (2131) 2131
protein kinase inhibitors - therapeutic use (1985) 1985
chronic myeloid leukemia (1936) 1936
mutation (1739) 1739
antineoplastic agents - pharmacology (1732) 1732
pharmacology & pharmacy (1653) 1653
mesylate (1638) 1638
mice (1565) 1565
leukemia, myelogenous, chronic, bcr-abl positive - genetics (1536) 1536
protein-tyrosine kinases - antagonists & inhibitors (1534) 1534
therapy (1473) 1473
pyrimidines - administration & dosage (1466) 1466
bcr-abl (1419) 1419
leukemia (1419) 1419
gastrointestinal stromal tumors - drug therapy (1405) 1405
piperazines - administration & dosage (1369) 1369
tyrosine kinase (1303) 1303
research (1290) 1290
prognosis (1261) 1261
pyrimidines - adverse effects (1249) 1249
drug resistance, neoplasm (1217) 1217
care and treatment (1203) 1203
leukemia, myelogenous, chronic, bcr-abl positive - pathology (1196) 1196
protein kinase inhibitors - pharmacology (1178) 1178
analysis (1156) 1156
cell line, tumor (1155) 1155
adolescent (1152) 1152
aged, 80 and over (1150) 1150
fusion proteins, bcr-abl - genetics (1150) 1150
tyrosine kinase inhibitor (1143) 1143
piperazines - adverse effects (1140) 1140
c-kit (1113) 1113
antineoplastic agents - adverse effects (1110) 1110
mesylates - pharmacology (1099) 1099
gastrointestinal stromal tumors (1093) 1093
mesylates - chemistry (1072) 1072
biochemistry & molecular biology (1055) 1055
tumors (1051) 1051
antineoplastic agents (1047) 1047
expression (1029) 1029
antineoplastic agents - administration & dosage (1002) 1002
time factors (1000) 1000
apoptosis (997) 997
hemic and lymphatic diseases (989) 989
dasatinib (988) 988
rats (955) 955
resistance (953) 953
chemotherapy (948) 948
dose-response relationship, drug (943) 943
young adult (937) 937
medicine & public health (930) 930
surgery (913) 913
gastrointestinal stromal tumors - pathology (906) 906
antimitotic agents (903) 903
cml (875) 875
tyrosine (873) 873
apoptosis - drug effects (871) 871
proto-oncogene proteins c-kit - genetics (852) 852
gist (847) 847
drug therapy (838) 838
cell biology (828) 828
imatinib mesylate - therapeutic use (814) 814
hematology, oncology and palliative medicine (786) 786
retrospective studies (777) 777
benzamides - therapeutic use (773) 773
gastrointestinal stromal tumor (764) 764
mutations (763) 763
in-vitro (761) 761
diagnosis (724) 724
inhibitor (708) 708
tyrosine kinase inhibitors (701) 701
mesylates (698) 698
efficacy (697) 697
fusion proteins, bcr-abl - metabolism (687) 687
follow-up studies (686) 686
survival (673) 673
health aspects (670) 670
disease-free survival (653) 653
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (18476) 18476
Japanese (479) 479
German (363) 363
French (350) 350
Chinese (323) 323
Italian (139) 139
Spanish (118) 118
Russian (108) 108
Polish (47) 47
Portuguese (40) 40
Korean (33) 33
Czech (27) 27
Hungarian (27) 27
Danish (12) 12
Dutch (12) 12
Croatian (10) 10
Swedish (10) 10
Romanian (8) 8
Bulgarian (5) 5
Slovak (4) 4
Finnish (3) 3
Hebrew (3) 3
Norwegian (3) 3
Serbian (3) 3
Turkish (3) 3
Ukrainian (3) 3
Indonesian (1) 1
Lithuanian (1) 1
Slovenian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The lancet oncology, ISSN 1470-2045, 2011, Volume 12, Issue 11, pp. 1045 - 1052
Journal Article
Journal Article
Journal Article
Journal Article
European Journal of Cancer, ISSN 0959-8049, 2016, Volume 52, pp. 173 - 180
Abstract Background The added value of tumoural genomic profiles to conventional clinico-biological factors to predict progression-free survival (PFS) and... 
Hematology, Oncology and Palliative Medicine | GIST | prognostic factors | outcome analysis | imatinib mesylate | mutational status | RESEARCH GEIS | FREE SURVIVAL | PHASE-III | KIT EXON-11 | MESYLATE | PROGNOSTIC-FACTOR | SPANISH GROUP | ONCOLOGY | MUTATIONS | GASTROINTESTINAL STROMAL TUMORS | INTERRUPTION | Predictive Value of Tests | Gastrointestinal Neoplasms - genetics | Exons | Gastrointestinal Neoplasms - drug therapy | Gastrointestinal Neoplasms - mortality | Humans | Male | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | Gastrointestinal Neoplasms - pathology | Time Factors | Antineoplastic Agents - adverse effects | DNA Mutational Analysis | Gastrointestinal Stromal Tumors - pathology | Imatinib Mesylate - adverse effects | Imatinib Mesylate - administration & dosage | Female | Proto-Oncogene Proteins c-kit - genetics | Gastrointestinal Stromal Tumors - mortality | France | Gastrointestinal Stromal Tumors - genetics | Risk Factors | Kaplan-Meier Estimate | Proportional Hazards Models | Treatment Outcome | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Gastrointestinal Stromal Tumors - drug therapy | Biomarkers, Tumor - genetics | Mutation | Antimitotic agents | Care and treatment | Sarcoma | Antineoplastic agents | Patient outcomes | Standards | Life Sciences | Cancer
Journal Article
Proceedings of the National Academy of Sciences of the United States of America, ISSN 0027-8424, 10/2006, Volume 103, Issue 40, pp. 14907 - 14912
Journal Article
Journal Article
Biological & pharmaceutical bulletin, ISSN 0918-6158, 2015, Volume 38, Issue 3, pp. 411 - 416
Journal Article
Xenobiotica, ISSN 0049-8254, 6/2013, Volume 43, Issue 6, pp. 498 - 508
1. This work investigated the drug interaction potential of GSK1292263, a novel GPR119 agonist, with the HMG-coA reductase inhibitors simvastatin and... 
P-glycoprotein | BCRP | transporters | Cytochrome P450 | OATP | dyslipidemia | diabetes | pharmacogenetics | Pharmacogenetics | Dyslipidemia | Transporters | Diabetes | POLYMORPHISM MARKEDLY AFFECTS | SLCO1B1 POLYMORPHISM | ATORVASTATIN | INHIBITION | PHARMACOKINETICS | FLUVASTATIN | PHARMACOLOGY & PHARMACY | TOXICOLOGY | SIMVASTATIN | Fluorobenzenes - pharmacokinetics | Pyrroles - pharmacokinetics | Simvastatin - adverse effects | Pyrimidines - blood | Humans | Hydroxymethylglutaryl-CoA Reductase Inhibitors - blood | Middle Aged | Male | Heptanoic Acids - adverse effects | Simvastatin - pharmacology | Fluorobenzenes - pharmacology | Young Adult | Drug Interactions | Piperidines - pharmacology | Oxadiazoles - pharmacology | Madin Darby Canine Kidney Cells | Pyrroles - adverse effects | Oxadiazoles - pharmacokinetics | Heptanoic Acids - pharmacology | Mesylates - blood | Troleandomycin - adverse effects | Rosuvastatin Calcium | Mesylates - adverse effects | Pyrimidines - pharmacology | Sulfonamides - pharmacology | Simvastatin - analogs & derivatives | Sulfonamides - pharmacokinetics | Oxadiazoles - adverse effects | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology | Cytochrome P-450 CYP3A - metabolism | Adolescent | Atorvastatin | Pyrimidines - pharmacokinetics | Oxadiazoles - blood | Demography | Heptanoic Acids - pharmacokinetics | Mesylates - pharmacokinetics | Simvastatin - blood | Piperidines - blood | Troleandomycin - pharmacokinetics | Dose-Response Relationship, Drug | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacokinetics | Sulfonamides - blood | Reference Standards | Adult | Female | Piperidines - pharmacokinetics | Troleandomycin - pharmacology | Fluorobenzenes - blood | Pyrroles - blood | Simvastatin - pharmacokinetics | Pyrroles - pharmacology | Animals | Cytochrome P-450 CYP3A Inhibitors | Mesylates - pharmacology | Piperidines - adverse effects | Dogs | Pyrimidines - adverse effects | Sulfonamides - adverse effects | Aged | Fluorobenzenes - adverse effects | Heptanoic Acids - blood
Journal Article
Haematologica (Roma), ISSN 1592-8721, 2016, Volume 101, Issue 6, pp. 717 - 723
Journal Article
Journal Article